The Utility of Early Broncholaveolar Lavage in Prolonged Neutropenic Patients with Pulmonary Nodules by Khalaf, Dina, Chan, Steven M., Gupta, Vikas, Lutynski, Andrzej, Maze, Dawn, Minden, Mark D., Natori, Yoichiro, Pavan, Rhea, Rostom, Amr, Rydlewski, Anna, Schimmer, Aaron, Schuh, Andre, Sibai, Hassan, Yee, Karen W.L., Husain, Shahid

Get full text

A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy by Brandwein, Joseph M., Seki, Jack T., Atenafu, Eshetu G., Rostom, Amr, Lutynski, Andrzej, Rydlewski, Anna, Schimmer, Aaron D., Schuh, Andre C., Gupta, Vikas, Yee, Karen W. L.

Get full text

Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived by Farshchi Zarabi, Sara, Chan, Steven M., Gupta, Vikas, Khalaf, Dina, Lutynski, Andrzej, Minden, Mark D., Rostom, Amr, Rydlewski, Anna, Schuh, Andre C., Sibai, Hassan, Yee, Karen W.L., Schimmer, Aaron D.

Get full text

Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome by Kavanagh, Simon, Heath, Emily, Hurren, Rose, Barghout, Samir H., Liyanage, Sanduni U., Siriwardena, Thirushi, Claudio, Jaime, Zhang, Tong, Sukhai, Mahadeo, Stockley, Tracy L., Kamel-Reid, Suzanne, Rostom, Amr, Khalaf, Dina, Lutynski, Andrzej, Rydlewski, Anna, Schuh, Andre C., Gupta, Vikas, Sibai, Hassan, Maze, Dawn, Chan, Steven M., Schimmer, Aaron D.

Get full text

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7 by Bhella, Sita D., Atenafu, Eshetu G, Schuh, Andre C, Minden, Mark D., Schimmer, Aaron D., Gupta, Vikas, Seftel, Matthew D., Shanavas, Mohamed, Lutynski, Andrzej, Rostom, Amr, Rydlewski, Anna, Khalaf, Dina, Yee, Karen W.L.

Get full text

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review by Bhella, Sita D., Atenafu, Eshetu G, Brandwein, Joseph, Gupta, Vikas, Hitzler, Johann, Khalaf, Dina, Lutynski, Andrzej, Schimmer, Aaron D., Schuh, Andre C, Rostom, Amr, Rydlewski, Anna, Yee, Karen W.L., Minden, Mark D.

Get full text

AML refractory to primary induction with Ida-FLAG has a poor clinical outcome by Kavanagh, Simon, Heath, Emily, Hurren, Rose, Gronda, Marcela, Barghout, Samir H., Liyanage, Sanduni U., Siriwardena, Thirushi P., Claudio, Jaime, Zhang, Tong, Sukhai, Mahadeo, Stockley, Tracy L., Kamel-Reid, Suzanne, Rostom, Amr, Lutynski, Andrzej, Khalaf, Dina, Rydlewski, Anna, Chan, Steven M., Gupta, Vikas, Maze, Dawn, Sibai, Hassan, Schuh, Andre C., Yee, Karen, Minden, Mark D., Schimmer, Aaron D.

Get full text

Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived by Farshchi Zarabi, Sara, Chan, Steven, Gupta, Vikas, Khalaf, Dina, Lutynski, Andrzej, Minden, Mark D., Rostom, Amr, Rydlewski, Anna, Schuh, Andre C., Sibai, Hassan, Yee, Karen W. L., Schimmer, Aaron D.

Get full text

Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis by Deotare, Uday, Shaheen, Marwan, Brandwein, Joseph M., Gill, Bethany, Kamel-Reid, Suzanne, Yee, Karen W.L., Rydlewski, Anna, Lutynski, Andrzej, Rostom, Amr, Schimmer, Aaron D, Minden, Mark D., Gupta, Vikas, Seftel, Matthew D., Alam, Naheed, Schuh, Andre C

Get full text

FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML) by Bhella, Sita D., Atenafu, Eshetu G, Schuh, Andre C, Minden, Mark D, Schimmer, Aaron D, Gupta, Vikas, Seftel, Matthew D., Alam, Naheed, Lutynski, Andrzej, Rostom, Amr, Rydlewski, Anna, Yee, Karen

Get full text